title: [Puberty-delaying hormone therapy in adolescents with gender identity disorder].
abstract: The guideline for the treatment of people with gender identity disorder (GID) of the Japanese Society of Psychiatry and Neurology was revised in January 2012. The guideline eased restrictions for the endocrine treatment of transsexual adolescents. A medical specialist can start treating transsexual adolescents at the age of 15 after the diagnosis of GID. It recommends that transsexual adolescents (Tanner stage 2 [mainly 12-13 years of age]) are treated by endocrinologists to suppress puberty with gonadotropin-releasing hormone (GnRH) agonists until the age of 15 years old, after which cross-sex hormones may be given. Female-to-male transsexuals do not necessarily want to start androgen therapy before presenting female secondary sexual characteristics because androgen can easily stop menstruation, cause beard growth, and lower the voice. On the contrary, male-to-female transsexuals want to start estrogen therapy before presenting male secondary sexual characteristics because estrogen cannot alter the beard and low voice. It is important to identify children with gender dysphoria in school and help them receive medical advice. However, approximately half of school teachers think that children with gender dysphoria are very rare and they do not know of the notification from Ministry of Education, Culture, Sports, Science and Technology, JAPAN, which aims to help children with gender dysphoria. The revision of the guideline for the treatment of transsexual people and endocrine treatment of transsexual adolescents by medical specialists may prevent them from attempting suicide, being depressive, and refusing to attend school. Furthermore, the treatment may help avoid mental disorders, aid being employed with the desired sexuality, and, subsequently, getting married and having children.
authors.affiliation: Graduate School of Health Sciences, Okayama University, Department of Obstetrics and Gynecology, Gender Clinic, Okayama University Hospital, Japanese Society of Gender Identity Disorder.
authors.forename: Mikiya
authors.initials: M
authors.lastname: Nakatsuka
mesh_terms: D000293:Adolescent; D002653:Child Behavior Disorders / Q000188:drug therapy*; D005783:Gender Identity; D012739:Gonadal Steroid Hormones / Q000096:biosynthesis* / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000096:biosynthesis*; D006801:Humans; D007564:Japan; D017410:Practice Guidelines as Topic / Q000592:standards; D011627:Puberty / Q000502:physiology / Q000523:psychology*; D014189:Transsexualism / Q000175:diagnosis / Q000628:therapy
chemical_list: D012739:Gonadal Steroid Hormones; D007987:Gonadotropin-Releasing Hormone